Literature DB >> 16516535

Pathogenic superoxide dismutase structure, folding, aggregation and turnover.

P John Hart1.   

Abstract

Significant advances have been made during the past two years toward an understanding of the molecular basis for how mutations in human cytosolic copper-zinc superoxide dismutase (SOD1) cause the inherited form of amyotrophic lateral sclerosis (ALS). Biophysical studies suggest that the pathogenic mutations destabilize loop or beta-barrel structural elements of the protein. With few exceptions, the loss of metal ions and reduction of the intrasubunit disulfide bond enhance this destabilization. In mouse models of the disease, the formation of visible aggregates containing mutant SOD1 occurs relatively late in the lifespan, hinting that the quality control and protein turnover systems of motor neurons eventually become overwhelmed or compromised. Studies probing SOD1 turnover have suggested the possibility that proteolytic breakdown products may play a role in pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16516535     DOI: 10.1016/j.cbpa.2006.02.034

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN: 1367-5931            Impact factor:   8.822


  42 in total

1.  Intermolecular transmission of superoxide dismutase 1 misfolding in living cells.

Authors:  Leslie I Grad; Will C Guest; Anat Yanai; Edward Pokrishevsky; Megan A O'Neill; Ebrima Gibbs; Valentyna Semenchenko; Masoud Yousefi; David S Wishart; Steven S Plotkin; Neil R Cashman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

2.  Structures of mouse SOD1 and human/mouse SOD1 chimeras.

Authors:  Sai V Seetharaman; Alexander B Taylor; Stephen Holloway; P John Hart
Journal:  Arch Biochem Biophys       Date:  2010-08-19       Impact factor: 4.013

3.  Cargo distributions differentiate pathological axonal transport impairments.

Authors:  Cassie S Mitchell; Robert H Lee
Journal:  J Theor Biol       Date:  2012-01-25       Impact factor: 2.691

4.  Impaired post-translational folding of familial ALS-linked Cu, Zn superoxide dismutase mutants.

Authors:  Cami K Bruns; Ron R Kopito
Journal:  EMBO J       Date:  2007-01-25       Impact factor: 11.598

5.  Disease-associated mutations at copper ligand histidine residues of superoxide dismutase 1 diminish the binding of copper and compromise dimer stability.

Authors:  Jiou Wang; Amy Caruano-Yzermans; Angela Rodriguez; Jonathan P Scheurmann; Hilda H Slunt; Xiaohang Cao; Jonathan Gitlin; P John Hart; David R Borchelt
Journal:  J Biol Chem       Date:  2006-11-08       Impact factor: 5.157

Review 6.  Motor neuron trophic factors: therapeutic use in ALS?

Authors:  Thomas W Gould; Ronald W Oppenheim
Journal:  Brain Res Rev       Date:  2010-10-21

7.  Progressive aggregation despite chaperone associations of a mutant SOD1-YFP in transgenic mice that develop ALS.

Authors:  Jiou Wang; George W Farr; Caroline J Zeiss; Diego J Rodriguez-Gil; Jean H Wilson; Krystyna Furtak; D Thomas Rutkowski; Randal J Kaufman; Cristian I Ruse; John R Yates; Steve Perrin; Mel B Feany; Arthur L Horwich
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

8.  Potential effect of S-nitrosylated protein disulfide isomerase on mutant SOD1 aggregation and neuronal cell death in amyotrophic lateral sclerosis.

Authors:  Gye Sun Jeon; Tomohiro Nakamura; Jeong-Seon Lee; Won-Jun Choi; Suk-Won Ahn; Kwang-Woo Lee; Jung-Joon Sung; Stuart A Lipton
Journal:  Mol Neurobiol       Date:  2013-10-04       Impact factor: 5.590

9.  HDAC6 regulates mutant SOD1 aggregation through two SMIR motifs and tubulin acetylation.

Authors:  Jozsef Gal; Jing Chen; Kelly R Barnett; Liuqing Yang; Erin Brumley; Haining Zhu
Journal:  J Biol Chem       Date:  2013-04-11       Impact factor: 5.157

10.  Cytosolic superoxide dismutase (SOD1) is critical for tolerating the oxidative stress of zinc deficiency in yeast.

Authors:  Chang-Yi Wu; Janet Steffen; David J Eide
Journal:  PLoS One       Date:  2009-09-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.